Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.

Objective: To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).

Methods: The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.

Results: The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).

Conclusions: The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.